, Tracking Stock Market Picks
Enter Symbol:
Rating: GPRO
Overweight $40
down 58.00 %

Gopro Inc. (NASDAQ: GPRO) reiterated to Overweight with price target $40 by Barclays

Thursday,  Oct 29, 2015  2:25 PM ET by Dave Ficere

Barclays reiterated Gopro Inc. (NASDAQ: GPRO) to Overweight with price target $40. Previously Barclays rated Overweight with price target $71 Gopro Inc. (NASDAQ:
GPRO) on 07/22/2015, when the stock price was $60.91. Since then, Gopro Inc.'s stock price has lost 58% as of 10/29/2015's recent price of $25.69.
If you would have followed the previous Barclays's recommendation on GPRO, you would have lost 58% of your investment in 99 days.

Gen-Probe Inc. is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing (NAT) products used for the clinical diagnosis of human diseases and for screening donated human blood. Using its patented NAT technology, Gen-Probe has received FDA approvals for more than 40 products that detect a wide variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy